Takeda, in alignment with the U.S. Food and Drug Administration (FDA), will close the U.S. Special Use Program (SUP) for NATPARA® (parathyroid hormone) for Injection at the end of 2025. TAKEDA WILL CEASE SHIPMENTS OF NATPARA BY DECEMBER 31, 2025 AND NATPARA WILL NO LONGER BE AVAILABLE TO SUP PATIENTS. Learn How This May Affect You
NATPARA® is a parathyroid hormone indicated as an adjunct to calcium and vitamin D to control hypocalcemia in patients with hypoparathyroidism. Because of the potential risk of osteosarcoma, NATPARA is recommended only for patients who cannot be well-controlled on calcium supplements and active forms of vitamin D alone. NATPARA was not studied in patients with hypoparathyroidism caused by calcium-sensing receptor mutations. NATPARA was not studied in patients with acute post-surgical hypoparathyroidism.
See full indication
See less indication
NATPARA® is a parathyroid hormone indicated as an adjunct to calcium and vitamin D to control hypocalcemia in patients with hypoparathyroidism. Because of the potential risk of osteosarcoma, NATPARA is recommended only for patients who cannot be well-controlled on calcium supplements and active forms of vitamin D alone. NATPARA was not studied in patients with hypoparathyroidism caused by calcium-sensing receptor mutations. NATPARA was not studied in patients with acute post-surgical hypoparathyroidism.
See full indication
See less indication
For patients with hypoparathyroidism
What is the right calcium balance?
Find out how NATPARA was able to affect serum calcium levels as an adjunct to calcium and vitamin D in patients with hypoparathyroidism1
